Literature DB >> 22387181

Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach.

A Fairchild1, R Bar-Deroma, L Collette, K Haustermans, C Hurkmans, D Lacombe, P Maingon, P Poortmans, M Tomsej, D C Weber, V Gregoire.   

Abstract

The European Organisation for Research and Treatment of Cancer (EORTC) Master Protocol for phase III radiation therapy (RT) studies was published in 1995 to define in a consistent sequence the parameters which must be addressed when designing a phase III trial 'from the rationale to the references'. This was originally implemented to assist study investigators and writing committees, and to increase homogeneity within Radiation Oncology Group (ROG) study protocols. However, RT planning, delivery, treatment verification and quality assurance (QA) have evolved significantly over the last 15 years and clinical trial protocols must reflect these developments. The goal of this update is to describe the incorporation of these developments into the EORTC-ROG protocol template. Implementation of QA procedures for advanced RT trials is also briefly described as these essential elements must also be clearly articulated. This guide may assist both investigators participating in current ROG trials and others involved in writing an advanced RT trial protocol.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22387181     DOI: 10.1016/j.ejca.2012.02.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.

Authors:  Alysa Fairchild; Johannes A Langendijk; Sandra Nuyts; Christopher Scrase; Milan Tomsej; Danny Schuring; Akos Gulyban; Sunita Ghosh; Damien C Weber; Wilfried Budach
Journal:  Radiat Oncol       Date:  2014-11-26       Impact factor: 3.481

2.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

3.  A dummy-run evaluation of postoperative hypofractionated intensity-modulated radiation therapy (POHIM-RT) trials for cervical cancer.

Authors:  Won Kyung Cho; Heejung Kim; Won Park; Sang-Won Kim; Jongwon Kim; Kang Kyu Lee; Jeong Geun Oh; Mee Sun Yoon; Ju-Young Song; Ki Jung Ahn; Sung Kwang Park; Jin Hwa Choi; Jino Bak
Journal:  J Radiat Res       Date:  2021-01-01       Impact factor: 2.724

Review 4.  Demystifying radiation oncology clinical trial concerns for protocol scientific review and institutional review board committee members.

Authors:  Jamiluddin Qazi; Kristi A DeHaai; Benjamin M Hawkins; Kara D Romano; Nicholas G Zaorsky; Ronald C Chen; Timothy N Showalter
Journal:  Contemp Clin Trials Commun       Date:  2022-03-19

5.  Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer.

Authors:  N Groom; E Wilson; E Lyn; C Faivre-Finn
Journal:  Br J Radiol       Date:  2014-03-13       Impact factor: 3.039

6.  Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study.

Authors:  Takahisa Eriguchi; Atsuya Takeda; Yohei Oku; Satoshi Ishikura; Tomoki Kimura; Shuichi Ozawa; Takeo Nakashima; Yukinori Matsuo; Mitsuhiro Nakamura; Yasuo Matsumoto; Sadanori Yamazaki; Naoko Sanuki; Yoshinori Ito
Journal:  Radiat Oncol       Date:  2013-05-04       Impact factor: 3.481

7.  Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective.

Authors:  Marie Lambrecht; Christos Melidis; Jan-Jakob Sonke; Sonja Adebahr; Ronald Boellaard; Marcel Verheij; Matthias Guckenberger; Ursula Nestle; Coen Hurkmans
Journal:  Radiat Oncol       Date:  2016-01-20       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.